Lonza Group AG Acquires Synaffix B.V.
June 1, 2023
Lonza Group AG has acquired Synaffix B.V., a Netherlands-based biotech company that commercialises a clinical-stage antibody-drug conjugate (ADC) technology platform. The deal brings Synaffix's ADC bioconjugation technology into Lonza's integrated ADC development and manufacturing offering to accelerate discovery, development, scale-up and commercialization of ADCs.
- Buyers
- Lonza Group AG
- Targets
- Synaffix B.V.
- Industry
- Biotechnology
- Location
- Netherlands
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.